About Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1
Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1) is a protein
from Homo sapiens identified by UniProt accession
Q9NS00, 363 residues long.
MolForge cross-references it against 0 known binders and
203 disease associations.
Target properties
| Protein name | Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 |
| UniProt accession | Q9NS00 |
| Gene | C1GALT1 |
| Organism | Homo sapiens |
| Length | 363 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (203)
Diseases linked to this target (Open Targets).
- diastolic blood pressure · score 0.46
- FEV/FVC ratio · score 0.44
- aspartate aminotransferase measurement · score 0.43
- hypertension · score 0.41
- serum galactose-deficient IgA1 measurement · score 0.38
- cortical thickness · score 0.37
- carcinoma · score 0.37
- diabetes mellitus · score 0.36
- cardiovascular disease · score 0.36
- forced expiratory volume · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NS00-F1 | alphafold | PREDICTED | 88.22 | — |
Amino-acid sequence (363 residues)
MASKSWLNFL TFLCGSAIGF LLCSQLFSIL LGEKVDTQPN VLHNDPHARH SDDNGQNHLE GQMNFNADSS QHKDENTDIA ENLYQKVRIL CWVMTGPQNL EKKAKHVKAT WAQRCNKVLF MSSEENKDFP AVGLKTKEGR DQLYWKTIKA FQYVHEHYLE DADWFLKADD DTYVILDNLR WLLSKYDPEE PIYFGRRFKP YVKQGYMSGG AGYVLSKEAL KRFVDAFKTD KCTHSSSIED LALGRCMEIM NVEAGDSRDT IGKETFHPFV PEHHLIKGYL PRTFWYWNYN YYPPVEGPGC CSDLAVSFHY VDSTTMYELE YLVYHLRPYG YLYRYQPTLP ERILKEISQA NKNEDTKVKL GNP
Explore Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets